Madrigal Pharmaceuticals (FRA:YDO1) Net Issuance of Debt

: €60.59 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Madrigal Pharmaceuticals's net issuance of debt for the three months ended in Dec. 2023 was €0.00 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Dec. 2023 was €60.59 Mil.

Madrigal Pharmaceuticals Net Issuance of Debt Historical Data

The historical data trend for Madrigal Pharmaceuticals's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Madrigal Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Debt

47.20

59.61

Madrigal Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Issuance of Debt																-	32.69	13.85	14.06	-

Madrigal Pharmaceuticals Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €60.59 Mil.

Madrigal Pharmaceuticals Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Madrigal Pharmaceuticals's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Madrigal Pharmaceuticals (FRA:YDO1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (FRA:YDO1) » Definitions » Net Issuance of Debt

Comparable Companies

Traded in Other Exchanges

MDGL:USA

Address

200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428

Website

http://www.madrigalpharma.com

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Madrigal Pharmaceuticals (FRA:YDO1) Headlines

No Headlines